- Open Access
SET protein up-regulated testosterone production in the cultured preantral follicles
Reproductive Biology and Endocrinologyvolume 11, Article number: 9 (2013)
We found previously that the expression of SET gene was up-regulated in polycystic ovaries. Evidences suggested that SET protein was essential for regulating both the promoter activity of CYP17A1 and the biological activity of P450c17. In this study, we explored whether SET regulated androgen production in preantral follicles.
The mouse preantral follicles were cultured in vitro. Testosterone secretion and expression of steroidogenic enzymes were observed in the preantral follicles treated in vitro by SET overexpression and knockdown.
Testosterone levels in the media of the AdCMV-SET infected follicles significantly increased, and the CYP17A1 and HSD3B2 expression also significantly increased (P < 0.05). Testosterone levels in AdSiRNA-SET infected group decreased, and so did CYP17A1 and HSD3B2 expression (P < 0.05).
SET played a positive role in regulating ovarian androgen biosynthesis by enhancing the transcription of steroidogenic enzymes CYP17A1 and HSD3B2, which maybe contribute to the hyperandrogenism in PCOS.
The ovarian follicle develops as a functional unit which comprises of theca cells, granulosal cells, and oocyte. The theca cells are the primary source to synthesize androgen in response to LH [1–3]. Besides, the synthesis of androgen in theca cells is also regulated by a variety of additional steroidogenic enzymes. It is well known that theca cells express cytochrome P450 cholesterol side-chain cleavage enzyme (P450scc), 3β-hydroxysteroid dehydrogenase (HSD3B2), and cytochrome P450 cytochrome P450 17α-hydroxylase (CYP17A1) which has both 17α-hydroxylase and C17, 20 lyase activities . All of these are key enzymes for androgen synthesis. In addition, steroidogenic acute regulatory (StAR) protein which facilitates cholesterol entry into the mitochondria mediates the rate-limiting step in the synthesis of androgen . The regulation of these enzymes plays a critical role in normal androgen production and plays a proposed role in the pathogenic hyperandrogenic conditions such as Polycystic Ovarian Syndrome (PCOS) [6, 7].
The SET protein (patient “SE translocation”), also known as TAF-1β , I2PP2A  and INHAT , belongs to a family of multitasking proteins, which is involved in apoptosis, transcription, nucleosome assembly, and histone binding. SET is located in chromesome 9q34 and encodes a 39 KDa phosphoprotein. It was originally identified as a translocated gene in acute undifferentiated leukemia . In addition, as a transcriptional regulating factor, SET not only exerts by binding to the transcriptional co-activators CBP/p300 , but also acts directly as a transcriptional factor of CYP17A1 . SET-mediated promoter hypoacetylation is a prerequisite for co-activation of the estrogen-responsive pS2 gene by PRMT1 . SET is widely expressed in various tissues, especially in steroidogenic cells within the central nervous system, adrenal glands, and gonads [13, 15, 16]. In rat ovaries, SET protein expressed in theca cells and oocytes . In human ovaries we found that SET protein also expressed predominantly in theca cells and oocytes (unpublished data). Recent evidence suggested that SET was essential for regulating both the promoter activity of CYP17A1 and the biological activity of P450c17. In human NT2 neuronal precursor cells and MA-10 cells, SET binds to rat CYP17A1 promoter at −418/-399 and activates its basal transcription from a rat CYP17A1 luciferase reporter plasmid [13, 15, 17]. In addition, SET has been identified as a potent inhibitor of the protein phosphatase 2A (PP2A). Miller et al. showed that, in NCI-H295A cells, SET can foster 17, 20 lyase activity of P450c17 by inhibiting the dephosphorylation action of PP2A on P450c17 , because the phosphorylation of P450c17 on serine and threonine residues increases its17, 20 lyase activity through as-yet-unidentified mechanisms, which may involve in increasing its affinity for b5 and/or P450 oxidoreductase .
Although the function of SET protein in some steroidogenic cells such as adrenal glands cells has been partly studied, the role of SET in androgen biosynthesis of ovarian theca cells has not been explored previously. Our previous studies have also found that SET was one of the overexpressed genes in polycystic ovaries compared to normal ovaries using cDNA microarray technology . All of these attracted us to explore the function of SET in the regulation of ovarian androgen biosynthesis. This study may also help us to understand the pathophysiological role of SET in hyperandrogenism of PCOS.
Construction of recombinant adenovirus
The recombinant adenovirus was constructed using the AdEasy system . Briefly, the cDNA sequence of SET was cloned by reverse transcriptive polymerase chain reaction (RT-PCR), and then subcloned into pAdTrack-CMV. The AdCMV-SET was recombined with backbone pAdEasy-1 in BJ5183 bacteria. The recombined adenovirus AdCMV-SET was generated and amplified in 293A cells. The titer of the viral stock was determined by the tissue culture infectious dose (TCID50) method. At the same time, the adenovirus of AdCMV was generated using “empty” pAdTrack-CMV vector as the control.
For endogenous SET knockdown experiments, the recombinant adenoviruses AdsiRNA -SET delivering siRNA targeting SET and AdsiRNA-Scrambled (control) viruses were constructed as previously described, with some modifications . The potential target sequences for RNA interference were scanned with the siRNA Target Finder and Design Tool available on the Ambion Inc. website. The target sequence was as follows, SET SiRNA: 5′-ATATAACAAACTCCGCCAA-3′ (sense), SET Scramble: 5′-GAGACGTCAACTCCAACAC-3′. The target sequence was inserted into plasmid pShuttle-H1. The fragment H1-SiRNA/SET was digested and inserted into the plasmid pAdTrack-CMV to construct a shuttle plasmid containing reporter gene of green fluorescent protein (GFP). AdSiRNA-SET was recombined with backbone pAdEasy-1 in BJ5183 bacteria. The adenovirus of AdSiRNA-NS was constructed at the same time. Adenovirus generation, amplification, and titers were performed according to the methods described above.
Follicle isolation and culture
All animal procedures were approved by the Institutional Animal Care and Use Committee of Jiangsu Province and were performed in accordance with the Guide for the Care and Use of Laboratory Animals. Our follicle culture in vitro methods had been established previously [23, 24]. Briefly, ovaries were dissected immediately from 20-day-old female mice (Animal Centre of Nanjing Medical University, Nanjing, China) and transferred to the dissection medium, consisted of L-15 Leibovitz GlutaMAX (Gibco-BRL, Cergy-Pontoise, France) supplemented with 10% FCS, 100 IU/ml penicillin, and 100 μg/ml streptomycin that was prewarmed and maintained at 37°C. Ovaries were cleaned of connective tissues, and individual preantral follicles of 180–200 μm in diameter were isolated by manual dissection using 28.5-gauge needles (Becton Dickinson, Erembodegem, Belgium). Follicles were then transferred to the culture medium consisting of α-minimal essential medium (α-MEM; Gibco-BRL), 10% FCS, 100 mIU/ml recombinant follicle stimulating hormone (FSH; Gonal-F; Serono, Switzerland), and ITS with 5 mg/ml insulin, 5 mg/ml transferrin, and 5 ng/ml selenium (Sigma, USA). Only round follicles with intact basement membranes and theca layers were selected and placed individually in 96-well plates with 100 μl culture medium in each well and cultured at 37°C in a humidified atmosphere containing 5% CO2. Each treatment, respectively, was added in culture medium, as described in the results section. Specific treatments were performed in replicate and each experiment was repeated at least three independent times with a different preparation (pool) of follicles.
Follicle treatment with the recombinant adenoviruses
On the first day of follicle culture, the media was replaced with fresh media. Recombinant adenoviruses AdCMV-SET, AdCMV-GFP, AdSiRNA–SET, and AdSiRNA-scrambled were then separately added to culture media with a multiplicity of infection (MOI) of 100 and evenly distributed by gentle shaking. Virus expression was monitored by fluorescence microscopy showing green fluorescent protein (GFP). The infected follicles cultured for 24 h were harvested for qRT-PCR, with a total of 20 follicles in each group. At forty-eight hours after infection, the follicles were collected separately and stored at −80°C for later Western blot analysis, with a total of 40 follicles in each group. At the same time, the culture media of those infected for 48 h, were collected and stored at −80°C for steroid content assay, with a total of 20 follicles in each group. All experiments were repeated at least three times.
RNA extraction and qRT-PCR
RNA extraction of follicles was performed using the RNeasy Plus Micro Kit (Qiagen Inc, Chatsworth, CA) and total RNA was reverse transcribed with PrimeScript Reverse Transcription reagent Kit (Perfect Real Time), as described by the manufacturer. Amplification reactions were conducted using SYBR Premix Ex Taq (Perfect Real Time) with an ABI PRISM 7300 system. PrimeScript RT reagent Kit (Perfect Real Time) and SYBR Premix Ex Taq (Perfect Real Time) were purchased from TaKaRa Biotechnology (TaKaRa [Dalian] Co. Ltd, Dalian, China). Gene-specific qRT-PCR primers were used as listed in Table 1. GAPDH was employed as an internal control to normalize the loading templates of cDNA. Melting curve analysis was performed to confirm the specificity of qRT-PCR products. Each sample was assayed in duplicate and the fold changed in expression of each interested gene was analyzed via the 2-ΔΔCt method.
Testosterone level in the collected media was assessed using the radioimmunoassay (RIA) kits (Beifang Biotechnique Institute, Beijing, China) according to the manufacturer’s protocol. The RIA kits were sensitive (<0.02 ng/ml) and reproducible (total coefficient of variation [CV], <10%) with measurement range from 0.1 to 20 ng/ml.
Western blot analysis
The concentrations of protein extracted from the cultured follicles were measured by the Bradford method. Equal amount of protein was loaded and separated by 12% SDS-PAGE and then electroblotted onto Polyvinylidene fluoride membrane (Bio-Rad, Hercules, CA). The membranes were incubated with antibodies of target protein and then with HRP-conjugated secondary antibodies (1:1000; Beijing ZhongShan Biotechnology, China) and examined by enhanced chemiluminescence (Amersham Biosciences, Uppsala, Sweden). At last the results were analyzed by Quantity One version 4.6.2 (Bio-Rad, USA). The first antibodies used were: polyclonal antibody to human SET protein at 1:1000 dilution from ABCAM (Cambridge Science Park, Cambridge, UK); polyclonal antibody to mouse SET protein at 1:1000 from Santa Cruz Biotechnology (Santa Cruz, CA, USA); polyclonal antibody to β-tublin (as working calibrator) at 1:2000 from ABCAM (Cambridge Science Park, Cambridge, UK).
Data were expressed as mean ± SD from at least three independent experiments. One-way ANOVA was used for statistical comparison. Values were determined to be significant when p < 0.05.
SET overexpression promoted androgen production in theca cells
The in vitro culture model of mouse preantral follicle was used to study the effect of SET on testosterone synthesis in theca cells. The recombinant adenovirus AdCMV-SET was constructed to up-regulate SET expression in theca cells of follicles. The report gene GFP was employed to indicate the efficiency of adenoviruses infection. At 24 h of post-infection, more than 90% of theca cells were infected as judged by the expression of GFP (Figure 1A). After 48 h, the expression of SET protein in follicles was analyzed by Western blot. SET protein in the follicles infected with AdCMV-SET was increased when compared with that in the follicles infected with AdCMV (p < 0.05, Figure 1B). To test whether SET regulated androgen production, the culture media of AdCMV-SET or AdCMV infected follicles were collected to evaluate testosterone levels. Compared with that in the AdCMV infected group, the testosterone level in the AdCMV-SET infected group was significantly increased (5.40 ± 0.80 ng/ml vs 10.09 ± 1.54 ng/ml, p < 0.05) (Figure 1C). These results indicated that SET promoted testosterone production in ovarian theca cells.
SET knockdown suppressed androgen production in theca cells
To further confirm the effect of SET in modulating androgen synthesis in theca cells, analogous experiments were performed using AdSiRNA-SET and AdSiRNA-NS control adenoviruses. After 24 h of infection, more than 90% of theca cells were observed to express GFP (Figure 2A). As anticipated, level of SET protein was degraded about 43% in the follicles treated with AdSiRNA-SET when compared to that in the AdSiRNA-NS treated follicles (p < 0.05, Figure 2B). When compared with that in control group, testosterone accumulation in the media of AdSiRNA-SET infection group was significantly decreased (5.64 ± 1.40 ng/ml vs 1.49 ± 0.32 ng/ml, p < 0.05) (Figure 2C). This functional study strongly demonstrated that SET protein had a positive role in modulating testosterone synthesis in ovarian theca cells.
SET regulated the transcription of steroidogenic enzymes in theca cells
To determine whether SET regulated testosterone production by increasing the expression of steroidogenic enzymes in theca cells, the mRNA levels of SET and steroidogenic enzymes, StAR, CYP11A1, CYP17A1, and HSD3B2, in the follicles infected with AdCMV-SET or AdCMV, and AdSiRNA-SET or AdSiRNA-NS, were investigated by qRT-PCR. Compared to the AdCMV group, the mRNA levels of CYP17A1 and HSD3B2 in the AdCMV-SET infected group were significantly augmented following SET overexpression in theca cells (Figure 3A, p < 0.05). Additionally, down-regulation of SET with AdSiRNA-SET was accompanied by the significantly lowered mRNA levels of CYP17A1 and HSD3B2 (Figure 3B, p < 0.05). Expression of StAR and CYP11A1 in groups of both SET overexpression or knockdown did not change significantly (Figure 3, p > 0.05).
The biosynthesis of androgen in ovarian follicles is regulated by a series of steroidogenic enzymes, such as P450scc, StAR, HSD3B2, CYP17A1. These enzymes exert important functions in normal androgen production and play a proposed role in the pathogenic conditions such as hyperandrogenism in PCOS [6, 7]. Previous studies showed that in PCOS theca cells the expression and activity of the P450c17 and 3β-HSD is elevated, and the CYP17A1 promoter activity is also increased [6, 25–29], which partly participated in hyperandrogenism of PCOS. In the past years, much attention has been focused on the regulation of androgen biosynthesis, while the mechanisms that control the expression of these steroidogenic enzymes remain not precisely elucidated. In this work, we explored the role of SET protein in androgen biosynthesis and modulation of steroidogenic enzymes.
Previous studies have shown that SET was widely expressed in various tissues, and especially in steroidogenic cells within the central nervous system, adrenal gland, and gonads. To understand the function of SET in human ovaries, SET expression patterns had been examined by immunohistochemistry, which showed that SET was expressed predominantly in theca cells and oocytes of the human ovarian follicles (unpublished data). This was in agreement with previous studies performed by Zhang et al.  showing that SET was expressed in theca cells and oocytes of rats. Since the expressions of a variety of steroidogenic enzymes are cell specific, the primary function of theca cells is to produce androgen. The expression of SET in theca cells indicates that SET may be involved in androgen biosynthesis.
The in vitro culture model of mouse preantral follicles mimicked the native ovary by maintaining similar structural integrity. Hormones and paracrine factors produced by granulosal and/or theca cells can regulate the physiological function of cells located on the opposite side of the basement membrane. The gene-manipulation procedure was previously confirmed to effectively deliver ectopical gene expression in follicular theca cells . In the present study, we developed the recombinant adenoviruses AdCMV-SET and AdSiRNA-SET to overexpress or knockdown SET gene in follicles. Our data firstly showed that overexpression of SET in theca cells promoted testosterone secretion. In contrast, down-regulation of SET led to a marked reduction in testosterone production. These results demonstrated that SET played a positive role in modulating testosterone secretion in follicular theca cells. In future study we will further examine the change of other androgens such as pregnenolone, androstenedione by chromatogram.
In ovarian theca cells, androgen biosynthesis is mediated by steroidogenic enzymes. Our further studies indicated that when SET was overexpressed in theca cells, expressions of CYP17A1 and HSD3B2 were significantly increased. As expected, the mRNA levels of CYP17A1 and HSD3B2 significantly decreased after SET was silenced in theca cells. Previous studies have shown that SET, as a novel transcriptional regulator, binds to the −410/-402 region of the rat CYP17A1 gene along with the transcription factors COUP-TF II, NGF-IB, and SF-1, and activates transcription of the rat P450c17 gene in neuronal precursor cells and mouse Leydig MA-10 cells [13, 15, 17]. Bioinformatical analysis showed that the SET binding sequences TCTCCTCAA is also present in the −312/-320 region of mouse CYP17A1 gene and a similar sequence ACTCCTCAG is present in the −964/-959 region of the mouse 3βHSD2 gene. Our present study indicated that SET may elevate the mRNA levels of CYP17A1 and HSD3B2 by promoting their transcription. Taken together, SET played a positive role in regulating ovarian androgen biosynthesis by enhancing transcription of CYP17 and HSD3B2, which may participate in hyperandrogenism of PCOS.
SET played a positive role in regulating ovarian testosterone biosynthesis by enhancing the transcription of steroidogenic enzymes CYP17A1 and HSD3B2, which maybe contribute to the hyperandrogenism in PCOS.
B-QX carried out the experimental work and statistics. L-LG participated in molecular work. Y-GC participated in principal and experimental design. LG is the Lab assistant. XD participated in molecular work. ML participated in molecular work. YZ participated in cell culture work. XM participated in experimental design. F-YD participated in experimental discussion. J-YL participated in principal and experimental design. All authors read and approved the final manuscript.
Cytochrome P450 17α-hydroxylase
Green fluorescent protein
Multiplicity of infection
P450 cholesterol side-chain cleavage enzyme
Polycystic ovarian syndrome
Protein phosphatase 2A
Reverse transcriptive polymerase chain reaction
Steroidogenic acute regulatory
Tissue culture infectious dose.
Doody KJ, Lorence MC, Mason JI, Simpson ER: Expression of messenger ribonucleic acid species encoding steroidogenic enzymes in human follicles and corpora lutea throughout the menstrual cycle. J Clin Endocrinol Metab. 1990, 70: 1041-1045. 10.1210/jcem-70-4-1041.
Saxena D, Escamilla-Hernandez R, Little-Ihrig L, Zeleznik AJ: Liver receptor homolog-1 and steroidogenic factor-1 have similar actions on rat granulosa cell steroidogenesis. Endocrinology. 2007, 148: 726-734.
Murayama C, Miyazaki H, Miyamoto A, Shimizu T: Involvement of Ad4BP/SF-1, DAX-1, and COUP-TFII transcription factor on steroid production and luteinization in ovarian theca cells. Mol Cell Biochem. 2008, 314: 51-58. 10.1007/s11010-008-9764-y.
Nakajin S, Hall PF: Microsomal cytochrome P-450 from neonatal pig testis. Purification and properties of A C21 steroid side-chain cleavage system (17 alpha-hydroxylase-C17,20 lyase). J Biol Chem. 1981, 256: 3871-3876.
Orly J, Stocco DM: The role of the steroidogenic acute regulatory (StAR) protein in female reproductive tissues. Horm Metab Res. 1999, 31: 389-398. 10.1055/s-2007-978761.
Nelson VL, Qin KN, Rosenfield RL, Wood JR, Penning TM, Legro RS, Strauss JF, McAllister JM: The biochemical basis for increased testosterone production in theca cells propagated from patients with polycystic ovary syndrome. J Clin Endocrinol Metab. 2001, 86: 5925-5933. 10.1210/jc.86.12.5925.
Wickenheisser JK, Nelson-Degrave VL, McAllister JM: Dysregulation of cytochrome P450 17alpha-hydroxylase messenger ribonucleic acid stability in theca cells isolated from women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2005, 90: 1720-1727.
Nagata K, Kawase H, Handa H, Yano K, Yamasaki M, Ishimi Y, Okuda A, Kikuchi A, Matsumoto K: Replication factor encoded by a putative oncogene, set, associated with myeloid leukemogenesis. Proc Natl Acad Sci U S A. 1995, 92: 4279-4283. 10.1073/pnas.92.10.4279.
Li M, Makkinje A, Damuni Z: The myeloid leukemia-associated protein SET is a potent inhibitor of protein phosphatase 2A. J Biol Chem. 1996, 271: 11059-11062. 10.1074/jbc.271.19.11059.
Seo SB, McNamara P, Heo S, Turner A, Lane WS, Chakravarti D: Regulation of histone acetylation and transcription by INHAT, a human cellular complex containing the set oncoprotein. Cell. 2001, 104: 119-130. 10.1016/S0092-8674(01)00196-9.
von Lindern M, van Baal S, Wiegant J, Raap A, Hagemeijer A, Grosveld G: Can, a putative oncogene associated with myeloid leukemogenesis, may be activated by fusion of its 3’ half to different genes: characterization of the set gene. Mol Cell Biol. 1992, 12: 3346-3355.
Karetsou Z, Martic G, Sflomos G, Papamarcaki T: The histone chaperone SET/TAF-Ibeta interacts functionally with the CREB-binding protein. Biochem Biophys Res Commun. 2005, 335: 322-327. 10.1016/j.bbrc.2005.06.210.
Compagnone NA, Zhang P, Vigne JL, Mellon SH: Novel role for the nuclear phosphoprotein SET in transcriptional activation of P450c17 and initiation of neurosteroidogenesis. Mol Endocrinol. 2000, 14: 875-888. 10.1210/me.14.6.875.
Wagner S, Weber S, Kleinschmidt MA, Nagata K, Bauer UM: SET-mediated promoter hypoacetylation is a prerequisite for coactivation of the estrogen-responsive pS2 gene by PRMT1. J Biol Chem. 2006, 281: 27242-27250. 10.1074/jbc.M605172200.
Zhang P, Compagnone NA, Fiore C, Vigne JL, Culp P, Musci TJ, Mellon SH: Developmental gonadal expression of the transcription factor SET and its target gene, P450c17 (17alpha-hydroxylase/c17,20 lyase). DNA Cell Biol. 2001, 20: 613-624. 10.1089/104454901753340604.
Nagata K, Saito S, Okuwaki M, Kawase H, Furuya A, Kusano A, Hanai N, Okuda A, Kikuchi A: Cellular localization and expression of template-activating factor I in different cell types. Exp Cell Res. 1998, 240: 274-281. 10.1006/excr.1997.3930.
Zhang P, Mellon SH: Multiple orphan nuclear receptors converge to regulate rat P450c17 gene transcription: novel mechanisms for orphan nuclear receptor action. Mol Endocrinol. 1997, 11: 891-904. 10.1210/me.11.7.891.
Pandey AV, Mellon SH, Miller WL: Protein phosphatase 2A and phosphoprotein SET regulate androgen production by P450c17. J Biol Chem. 2003, 278: 2837-2844. 10.1074/jbc.M209527200.
Zhang LH, Rodriguez H, Ohno S, Miller WL: Serine phosphorylation of human P450c17 increases 17,20-lyase activity: implications for adrenarche and the polycystic ovary syndrome. Proc Natl Acad Sci U S A. 1995, 92: 10619-10623. 10.1073/pnas.92.23.10619.
Diao FY, Xu M, Hu Y, Li J, Xu Z, Lin M, Wang L, Zhou Y, Zhou Z, Liu J, Sha J: The molecular characteristics of polycystic ovary syndrome (PCOS) ovary defined by human ovary cDNA microarray. J Mol Endocrinol. 2004, 33: 59-72. 10.1677/jme.0.0330059.
He TC, Zhou S, da Costa LT, Yu J, Kinzler KW, Vogelstein B: A simplified system for generating recombinant adenoviruses. Proc Natl Acad Sci U S A. 1998, 95: 2509-2514. 10.1073/pnas.95.5.2509.
Shen C, Buck AK, Liu X, Winkler M, Reske SN: Gene silencing by adenovirus-delivered siRNA. FEBS Lett. 2003, 539: 111-114. 10.1016/S0014-5793(03)00209-6.
Li M, Xue K, Ling J, Diao FY, Cui YG, Liu JY: The orphan nuclear receptor NR4A1 regulates transcription of key steroidogenic enzymes in ovarian theca cells. Mol Cell Endocrinol. 2010, 319: 39-46. 10.1016/j.mce.2010.01.014.
Fan L, Ling J, Ma X, Cui YG, Liu JY: Involvement of HSP10 during the ovarian follicular development of polycystic ovary syndrome: Study in both human ovaries and cultured mouse follicles. Gynecol Endocrinol. 2009, 25: 392-397. 10.1080/09513590902730796.
Nelson VL, Legro RS, Strauss JF, McAllister JM: Augmented androgen production is a stable steroidogenic phenotype of propagated theca cells from polycystic ovaries. Mol Endocrinol. 1999, 13: 946-957. 10.1210/me.13.6.946.
Wickenheisser JK, Quinn PG, Nelson VL, Legro RS, Strauss JF, McAllister JM: Differential activity of the cytochrome P450 17alpha-hydroxylase and steroidogenic acute regulatory protein gene promoters in normal and polycystic ovary syndrome theca cells. J Clin Endocrinol Metab. 2000, 85: 2304-2311. 10.1210/jc.85.6.2304.
Wood JR, Nelson VL, Ho C, Jansen E, Wang CY, Urbanek M, McAllister JM, Mosselman S, Strauss JF: The molecular phenotype of polycystic ovary syndrome (PCOS) theca cells and new candidate PCOS genes defined by microarray analysis. J Biol Chem. 2003, 278: 26380-26390. 10.1074/jbc.M300688200.
Wickenheisser JK, Nelson-DeGrave VL, Quinn PG, McAllister JM: Increased cytochrome P450 17alpha-hydroxylase promoter function in theca cells isolated from patients with polycystic ovary syndrome involves nuclear factor-1. Mol Endocrinol. 2004, 18: 588-605.
Schwartz JR, Roy SK: Expression of P450 side-chain cleavage (CYP11A1) and P450 17alpha-hydroxylase-17/20 lyase (CYP17) messenger ribonucleic acid in hamster primary interstitial cells in vitro: differential regulation of steroidogenesis by cyclic adenosine monophosphate. Biol Reprod. 2000, 63: 503-507. 10.1095/biolreprod63.2.503.
This work was supported by projects from China 973 program (2012CB944902, 2012CB944703) and National Foundation of Science (81070465). We gratefully acknowledge Drs. Zuomin Zhou and Jiahao Sha for their help in the molecular laboratory. We thank Dr Wang YF, Reproductive Biology Unit and Division of Reproductive Medicine, Ottawa Health Institute, for her help in English language.
The authors declare that they have no competing interests.
Boqun Xu, Lingling Gao contributed equally to this work.